CORDIS
EU research results

CORDIS

English EN
An Integrated Platform for Developing Brain Cancer Diagnostic Techniques

An Integrated Platform for Developing Brain Cancer Diagnostic Techniques

Objective

The mission of AiPBAND is to train a new generation of entrepreneurial and innovative early-stage researchers (ESRs) in the early diagnosis of brain tumours using molecular biomarkers in the blood, meeting the medical and societal challenges of this emerging field. AiPBAND will focus on gliomas, a range of devastating and progressive brain tumours affecting around 25,000 people each year in Europe and responsible for the majority of deaths from primary brain tumours.

Fourteen fellows will be trained by experts in 9 academic and 3 non-academic beneficiaries, belonging to 5 EU member states and 6 partner organizations (4 private sectors and 2 international academic), with fields ranging from neuroscience, engineering (including big data science), healthcare to economics. State-of-the-art technologies will be applied in parallel to (i) identify novel blood biomarkers from patients with gliomas, (ii) design three types of multiplex biosensor (plasmonic-based, graphene-based, and digital ELISA assay-based), (iii) develop a big data-empowered intelligent data management infrastructure, and (iv) develop cloud-based diagnostic systems. Proof-of-concept will be evaluated through clinical trials to assess accuracy, sensitivity and specificity. The elaborately designed individual research projects under the Vitae Researcher Development Framework – carefully arranged into local training courses, network wide events, secondments, personalized career development plans, with strong involvement of the private sector – will ensure exploitation of AiPBAND's achievements, and will maximize the ESRs’ abilities in creative & innovative thinking, triple-i knowledge transformation, and encourage a business-orientated mind-set and entrepreneurship.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY OF PLYMOUTH

Address

Drake Circus
Pl4 8aa Plymouth

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 819 863,64

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 273 287,88

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 273 287,88

STOCKHOLMS UNIVERSITET

Sweden

EU Contribution

€ 263 659,32

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 263 659,32

ISTITUTI FISIOTERAPICI OSPITALIERI

Italy

EU Contribution

€ 258 061,32

UNIVERSITA DEGLI STUDI DI CATANIA

Italy

EU Contribution

€ 258 061,32

SCRIBA NANOTECNOLOGIE SRL

Italy

EU Contribution

€ 258 061,32

MEDICAL TRIALS ANALYSIS ITALY SRL

Italy

EU Contribution

€ 258 061,32

THE HYVE BV

Netherlands

EU Contribution

€ 255 374,28

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 255 374,28

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 250 560

Partners (6)

Sort alphabetically

Expand all

ENGAGE - KEY TECHNOLOGY VENTURES AG

B. BRAUN MELSUNGEN AG

HUNAN UNIVERSITY

China Capital Medical University

Beijing Genome Institute

Biotecture Ltd

Project information

Grant agreement ID: 764281

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2021

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 687 311,88

  • EU contribution

    € 3 687 311,88

Coordinated by:

UNIVERSITY OF PLYMOUTH

United Kingdom